autologous dendritic cells-Jonsson Comprehensive Cancer Center-non-small cell lung cancer

This autologous dendritic cell vaccine is an investigational cellular immunotherapy developed by the Jonsson Comprehensive Cancer Center at UCLA for the treatment of non-small cell lung cancer (NSCLC). The therapy is a personalized vaccine produced by harvesting a patient's own dendritic cells (DCs) and maturing them in vitro. These mature DCs are then loaded with antigens derived from the patient's own irradiated tumor cells. When administered back to the patient, typically via intradermal injection, these antigen-presenting cells are intended to stimulate a robust, tumor-specific T-cell immune response. The primary goal of this approach is to eliminate residual cancer cells and prevent disease recurrence in patients with early-to-mid-stage NSCLC (Stages IB, II, and IIIA) who have undergone surgical resection.

Other names

autologous dendritic cell vaccinetherapeutic autologous dendritic cellsautologous tumor cell vaccinemature autologous dendritic cells loaded with irradiated autologous tumor cells